DiscoverUpToDate TalkEdoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis
Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

Update: 2018-02-20
Share

Description

Today’s UpToDate Talk episode features discussions related to three papers published in the New England Journal of Medicine. Dr. Jess Mandel discusses anticoagulation options for cancer-associated venous thromboembolism, and Dr. George Mallory discusses two studies of tezacaftor-ivacaftor in patients with cystic fibrosis. Segment two begins at 11:32 . Dr. Helen Hollingsworth hosts.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

Edoxaban vs low molecular weight heparin in cancer-related VTE; New treatment for cystic fibrosis

UpToDate